JLM-BIOCITY Meeting on
“Orphan Drugs on the Rise: A New Paradigm for the Future”
Tuesday, Jan 21th, 2019
The event will take place in the new building, Azrieli College of Engineering. Room C109, first floor, Bldg C (new building)

Karina Rubinstein, Director of Business Development, Start-Up Division at Israel Innovation Authority (IIA) will present the IIA’s ambitious BIO-CONVERGENCE program and funding opportunities.

Guest speakers are:

* Yuval Cabilly, General Partner, Israel Biotech Fund
* Techiya Toaff, Director, Regulatory Affairs, Navon Pharma Group
* Alon Bloomenfeld, CEO & co-founder, Raziel Therapeutics
* Yael Gruenbaum, Director, Medison Ventures
* Eran Ovadia, CEO, Immunity Pharma
* Rami Skaliter, CEO, Cell Cure Neurosciences

The discussion will focus on Orphan Drug Designation from both a regulatory and investor’s perspective, with several pharma companies sharing their experiences. Come and join us to hear inspiring and exceptional anecdotes!

In 1983, the United States Congress passed the Orphan Drugs Act designed to encourage the development of drugs for rare orphan diseases. Several countries in the EU followed suit in early 2000.

Because this different legislation has enabled regulatory authorities to facilitate the process for companies working in orphan drug development, more people with rare diseases around the world are able to be treated.

The advantages of a biotech company to invest in orphan drugs are several-fold. While there is a lack of competition, a great global medical need exists. Most large pharmaceutical companies are discouraged from spending huge amounts of resources on early-stage development of therapies in the orphan field, but at later developmental stages these companies understand the benefit in a small group of patients, with a very high revenue opportunity. Another benefit is the long patent protection period, which is a good incentive for investing in a company involved in orphan drugs. The introduction of an orphan drug on the market involves a considerable amount of investment, so the FDA gives these drugs several years more of exclusivity from the approval date.

JLM-BioCity is delighted to announce this event is sponsored by Azrieli College of Engineering and Atobe, Azrieli College’s Startup Entrepreneurship Center as well as Bio-Jerusalem.
the benefit in a small group of patients, with a minimum small market but very high revenue. Another benefit is the long patent protection periods offered by the authorities, for having decided as a company to invest in R&D. The introduction of an orphan drug on the market involves a considerable amount of investment, so the FDA gives these drugs several years more of exclusivity from the approval date.

The Orphan Drug Designation will be discussed from a regulatory point of view as well as an investor’s perspective and we will hear on the experience of several pharma companies.

JLM-BioCity is delighted to announce this event is sponsored by Azrieli College of Engineering and Atobe, Azrieli College’s Startup Entrepreneurship Center as well as Bio-Jerusalem.

The presentations will be in English.

NOTE: We ask you for a 20 NIS donation at the entrance to the event. The JLM-BioCity Team are all volunteers, but we have expenses to cover. Thank you for your donation in advance.

PLEASE RVSP ON THIS SITE AND SEND YOUR NAME IN HEBREW AND CAR LICENCE to the enclosed form:
https://forms.gle/nEGgzKvweqkKTaBZ7